TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07559513: Phase 3 Evaluation of the Safety, Pharmacokinetics, and Efficacy of Garetosmab (Anti-Activin A Monoclonal Antibody) in Children and Adolescents With Fibrodysplasia Ossificans Progressiva

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,314,560

Rescue Site Savings

+$7,448,752

Unlock Full NCT07559513 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07559513 Rescue Dossier →